						•									once, dur	ing the repo	rting period v	vhen such transaction	was underta	aken.	· ·
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of the related	Date of Audit	Value of	In case monie either party a the trans	s a result of		y financials inde ake or give loar				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Purchase of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-
2	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Purchase of goods or services		66	Amount as approved by the Audit Committee.			66	-	-	-		-	-	-	-	-	-	-
3	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Purchase of goods or services		131	Amount as approved by the Audit Committee.			131	-	-	-		-	-	-	-	-	-	-
4	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
5	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	,	-	-	-	-	-
6	Zydus Lifesciences Limited	Zydus Healthcare (USA) LLC	Subsidiary Company	Purchase of goods or services		9	Amount as approved by the Audit Committee.			9	-	-	-		-	-	-	-	-	-	-
7	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
8	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Purchase of goods or services		9	Amount as approved by the Audit Committee.			9	-	-	-		-	-	-	-	-	-	-
9	Zydus Lifesciences Limited	Sterling Biotech Limited	Joint Ventures	Purchase of goods or services		16	Amount as approved by the Audit Committee.			16	-	-	-		-	-	-	-	-	-	-
10	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives			5	Amount as approved by the Audit Committee.			5	-	-	-		-	-	-	-	-	-	-

															once, dur	ing the repo	rting period v	when such transaction	was underta	iken.	<u> </u>
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of the related	Date of Audit	Value of	In case monie either party a the trans	s a result of		y financials inde ake or give loar	ebtedness is i	ncurred to			of loans/ inv		
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
11	Zydus Lifesciences Limited	Oneiro Chemicals Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		399	Amount as approved by the Audit Committee.			399	-	-	-		-	-	-	-	-	-	-
12	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Purchase of fixed assets		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-
13	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Purchase of fixed assets		14	Amount as approved by the Audit Committee.			14	-	-	-		-	-	-	-	-	-	-
14	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives			13	Amount as approved by the Audit Committee.			13	-	-	-		-	-	-	-	-	-	-
15	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
16	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Purchase of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-
17	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Purchase of goods or services		807	Amount as approved by the Audit Committee.			807	-	-	-		-	-	-	-	-	-	-
18	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Purchase of goods or services		35	Amount as approved by the Audit Committee.			35	-	-	-		-	-	-	-	-	-	-
19	Zydus Lifesciences Limited	Vitely Bio LLP	Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
20	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives			3	Amount as approved by the Audit Committee.			3	-	-	-		-	-	-	-	-	-	-

															once, dur	ing the repo	rting period w	hen such transaction	was underta	iken.	
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of the related	Date of Audit	Value of	In case monie either party a the trans	s a result of		y financials ind ake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	audit	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
21	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Directors and/ or their relatives	Purchase of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-
22	Zydus Lifesciences Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		4	Amount as approved by the Audit Committee.			4	-	-	-		-	-	-	-	-	-	-
23	Zydus Lifesciences Limited	International Tax & Investment Consultants- Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		3	Amount as approved by the Audit Committee.			3	-	- -	-		-	-	-	-	-	-	-
24	Zydus Lifesciences Limited	Sahyadri Hospitals Private Limited	Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
25	Zydus Lifesciences Limited	Apollo Healthco Limited	Directors and/ or their relatives	Purchase of goods or services		10	Amount as approved by the Audit Committee.			10	-	-	-		-	-	-	-	-	-	-
26	Zydus Lifesciences Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		50	Amount as approved by the Audit Committee.			50	-	- -	-		-	-	-	-	-	-	-
27	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	422	Amount as approved by the Audit Committee.			422	-	-	-		-	-	-	-	-	-	-
28	Zydus Lifesciences Limited	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	40	Amount as approved by the Audit Committee.			40	-	-	-		-	-	-	-	-	-	-
29	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
30	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	13	Amount as approved by the Audit Committee.			13	-	-	-		-	-	-	-	-	-	-

		I			<u> </u>	1	1	1	T	1	T							hen such transaction			
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related	Remarks on	Value of the related	Date of Audit Committee	Value of	In case monie either party a the trans	s a result of	m	y financials ind ake or give loa				Details (of loans/ inve	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	approval by audit	party transaction ratified by the audit committee	Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
31	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	11	Amount as approved by the Audit Committee.			11	-	-	-		-	-	-	-	-	-	-
32	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	183	Amount as approved by the Audit Committee.			183	-	-	-		-	-	-	-	-	-	-
33	Zydus Lifesciences Limited	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	82	Amount as approved by the Audit Committee.			82	-	-	-		-	-	-	-	-	-	-
34	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	2	Amount as approved by the Audit Committee.			2	-	-	-		-	-	-	-	-	-	-
35	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	19	Amount as approved by the Audit Committee.			19	-	-	-		-	-	-	-	-	-	-
36	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-
37	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	14	Amount as approved by the Audit Committee.			14	-	-	-		-	-	-	-	-	-	-
38	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Reimbursement of Expenses paid	0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
39	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Any other transaction	Reimbursement of Expenses paid	4	Amount as approved by the Audit Committee.			4	-	-	-		-	-	-	-	-	-	-
40	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Any other transaction	Reimbursement of Expenses Recovered	6	Amount as approved by the Audit Committee.			6	-	-	-		-	-	-	-	-	-	-

				I	T	T	1	1	1	T	1							hen such transaction			· · · · · · · · · · · · · · · · · · ·
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related	Pamarka c-	Value of the related	Date of Audit Committee	Value of	In case monie either party a the trans	s a result of	m	y financials ind ake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
41	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Sale of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-
42	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Sale of goods or services		153	Amount as approved by the Audit Committee.			153	-	-	-		-	-	-	-	-	-	-
43	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
44	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services		411	Amount as approved by the Audit Committee.			411	-	-	-		-	-	-	-	-	-	-
45	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services		57,371	Amount as approved by the Audit Committee.			57,371	-	-	-		-	-	-	-	-	-	-
46	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		1,821	Amount as approved by the Audit Committee.			1,821	-	-	-		-	-	-	-	-	-	-
47	Zydus Lifesciences Limited	Zydus Healthcare Philippines Inc.	Subsidiary Company	Sale of goods or services		275	Amount as approved by the Audit Committee.			275	-	-	-		-	-	-	-	-	-	-
48	Zydus Lifesciences Limited	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Sale of goods or services		5	Amount as approved by the Audit Committee.			5	-	-	-		-	-	-	-	-	-	-
49	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Sale of goods or services		338	Amount as approved by the Audit Committee.			338	-	-	-		-	-	-	-	-	-	-
50	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Sale of goods or services		810	Amount as approved by the Audit Committee.			810	-	-	-		-	-	-	-	-	-	-

		T			1	1				1	1							hen such transaction			· · · · · · · · · · · · · · · · · · ·
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related	Remarks on	Value of the related	Date of Audit Committee	Value of	In case monie either party a the trans	s a result of	m	y financials ind ake or give loa				Details o	of loans/ inve	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	approval by audit committee	party transaction ratified by the audit committee	Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
51	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Sale of goods or services		602	Amount as approved by the Audit Committee.			602	-	-	-		-	-	-	-	-	-	-
52	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Sale of goods or services		313	Amount as approved by the Audit Committee.			313	-	-	-		-	-	-	-	-	-	-
53	Zydus Lifesciences Limited	Laboratorios Combix S.L.	Subsidiary Company	Sale of goods or services		145	Amount as approved by the Audit Committee.			145	-	-	-		-	-	-	-	-	-	-
54	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Sale of goods or services		180	Amount as approved by the Audit Committee.			180	-	-	-		-	-	-	-	-	-	-
55	Zydus Lifesciences Limited	Zydus Lifesciences Global FZE [UAE]	Company	Sale of goods or services		1,650	Amount as approved by the Audit Committee.			1,650	-	-	-		-	-	-	-	-	-	-
56	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Sale of goods or services		14	Amount as approved by the Audit Committee.			14	-	-	-		-	-	-	-	-	-	-
57	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Sale of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-
58	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
59	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Sale of fixed assets		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
60	Zydus Lifesciences Limited	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Sale of goods or services		(13)	Amount as approved by the Audit Committee.			(13)	-	-	-		-	-	-	-	-	-	-

															once, dur	ing the repo	rting period w	hen such transaction	was underta	iken.	
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of the related	Date of Audit	Value of	In case monie either party a the trans	s a result of		y financials ind nake or give load				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	audit	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
61	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Sale of fixed assets		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
62	Zydus Lifesciences Limited	Zydus Wellness Limited	Subsidiary Company	Sale of goods or services		4	Amount as approved by the Audit Committee.			4	-	-	-		-	-	-	-	-	-	-
63	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		9	Amount as approved by the Audit Committee.			9	-	-	-		-	-	-	-	-	-	-
64	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Sale of goods or services		3	Amount as approved by the Audit Committee.			3	-	-	-		-	-	-	-	-	-	-
65	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Sale of goods or services		5	Amount as approved by the Audit Committee.			5	-	-	-		-	-	-	-	-	-	-
66	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Sale of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-
67	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Sale of goods or services		18	Amount as approved by the Audit Committee.			18	-	-	-		-	-	-	-	-	-	-
68	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services		179	Amount as approved by the Audit Committee.			179	-	-	-		-	-	-	-	-	-	-
69	Zydus Lifesciences Limited		Subsidiary Company	Sale of goods or services		16	Amount as approved by the Audit Committee.			16	-	-	-		-	-	-	-	-	-	-
70	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		4	Amount as approved by the Audit Committee.			4	-	-	-		-	-	-	-	-	-	

															once, du	ing the repo	orting period v	when such transaction	was undert	aken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of the related	Date of Audit	Value of	In case monie either party a the trans	s a result of	in case an	y financials ind ake or give loa				Details	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
71	Zydus Lifesciences Limited	Zydus Therapeutics INC	Subsidiary Company	Sale of goods or services		35	Amount as approved by the Audit Committee.			35	-	-	-		-	-	-	-	-	-	-
72	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Sale of goods or services		2	Amount as approved by the Audit Committee.			2	-	-	-		-	-	-	-	-	-	-
73	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Sale of goods or services		31	Amount as approved by the Audit Committee.			31	-	-	-		-	-	-	-	-	-	-
74	Zydus Lifesciences Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Sale of goods or services		64	Amount as approved by the Audit Committee.			64	-	-	-		-	-	-	-	-	-	-
75	Zydus Lifesciences Limited	Zydus Medtech Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	0	-	-		-	-	-	-	-	-	-
76	Zydus Lifesciences Limited	Zydus Medtech Private Limited	Subsidiary Company	Investment		-	N.A.			1,395	-	1,395	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose
77	Zydus Lifesciences Limited	Zydus Medtech Private Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	0	Amount as approved by the Audit Committee.			0	-	-	-		-		-	-	-	-	-
78	Zydus Lifesciences Limited	Zydus Medtech Private Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	2	-		-	-	-	-	-	-	-
79	Zydus Lifesciences Limited	Zydus Medtech Private Limited	Subsidiary Company	Sale of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
80	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Sale of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
81	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	67	Amount as approved by the Audit Committee.			67	-	-	-		-	-	-	-	-	-	-

Amount in INR Million except stated otherwise Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. Details of the party entering In case monies are due to In case any financials indebtedness is incurred to Details of the counterparty Value of the Date of either party as a result of Details of loans/ investments /alue of the make or give loans/ investments the transaction related Audit the transaction related Value of Committee party Details of other Nature of party transaction Relationship Type of Related ransaction approval by Meeting Nature indebtedr Purpose for which related party ransaction during the of the (loan/ No **Party Transaction** as audit where the transactions ratified by reporting ess (loan/ Details of the funds will be Secured/ counterparty approved by committee ratification Opening Closing advance/ other Interest Rate (%) utilised by the Name Name the audit issuance Cost Tenure Tenure period with the lister the audit was balance balance intercorpora Unsecured of debt/ ndebtedness Itimate recipient of committee entity or its te deposit/ committee approved any other funds (endusage) subsidiary investment etc.) mount as Reimbursement ubsidiary Any other approved by 82 Zydus Lifesciences Limited of Expenses Zynext Ventures Pte. Ltd. the Audit Company transaction Recovered Committee. Zydus Lifesciences Global FZE Subsidiary 83 ydus Lifesciences Limited nterest received N.A. ompany Zydus Lifesciences Global FZE Subsidiary 6 Month SOFR + 240 Zydus Lifesciences Limited oan 1,745 Loans 5 Year Unsecured **Business Purpose** UAE] ompany Outstanding Zydus Lifesciences Global FZE Subsidiary Any other 85 Zydus Lifesciences Limited Receivables N.A. 1,715 [UAE] Company transaction Amount as Reimhursement Zvdus Lifesciences Global FZE Subsidiary Anv other approved by Zydus Lifesciences Limited of Expenses 300 300 [UAE] ransaction the Audit Recovered Committee Amount as Reimbursement Subsidiary Any other approved by Zydus Lifesciences Limited Zydus Wellness Limited of Expenses the Audit Company transaction Recovered Committee. Amount as Zydus Wellness Products Subsidiary Any other Reimbursement approved by Zydus Lifesciences Limited imited Company transaction of Expenses paid the Audit Committee Amount as Reimbursemen approved by Zydus Wellness Products Subsidiary Any other Zvdus Lifesciences Limited of Expenses transaction the Audit Limited Company Recovered Committee Amount as Reimbursement approved by Subsidiary Any other Zydus Lifesciences Limited Zydus Healthcare Limited of Expenses 24 24 Company transaction the Audit Recovered Committee Anv other Director Sitting Zydus Lifesciences Limited Mr. Pankaj R. Patel Managerial ransaction Personnel Key Zydus Lifesciences Limited Dr. Sharvil P. Patel Managerial temuneration 210 Personnel 93 Zydus Lifesciences Limited Mr. Ganesh N. Nayak Managerial Remuneration 70 Personnel Key 94 Zydus Lifesciences Limited Mr. Nitin D. Parekh Managerial 47 Remuneration N.A Personnel 95 Zydus Lifesciences Limited Mr. Dhaval N. Soni Managerial temuneration Personnel Subsidiary 96 Zydus Lifesciences Limited Dialforhealth Unity Limited nterest received N.A ompany

347

Zydus International Private

Zydus Lifesciences Limited

Subsidiary

Company

nterest received

Amount in INR Million except stated otherwise Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. Details of the party entering In case monies are due to In case any financials indebtedness is incurred to Details of the counterparty Value of the Date of either party as a result of Details of loans/ investments /alue of the make or give loans/ investments the transaction related Audit the transaction related Value of Committee party Details of other Nature of party transaction Relationship Type of Related ransaction approval by Meeting Nature indebtedr Purpose for which related party ransactio during the of the (loan/ No **Party Transaction** as audit where the transactions ratified by reporting ess (loan/ Details of the funds will be counterparty approved by committee ratification Opening Closing advance/ Secured/ other Interest Rate (%) utilised by the Name Name the audit issuance Cost Tenure Tenure period with the lister the audit was balance balance intercorpora Unsecured of debt/ ndebtedness ltimate recipient o committee entity or its te deposit/ committee approved any othe funds (endusage) subsidiary investment etc.) Zydus Pharmaceuticals (USA) Subsidiary 98 243 Zvdus Lifesciences Limited N.A nterest received ompany ubsidiary 99 257 Zydus Lifesciences Limited Sentynl Therapeutics Inc. nterest received N.A ompany Subsidiary 100 Zydus Lifesciences Limited Zydus Worldwide DMCC nterest received N.A 238 Company Amount as Subsidiary Sale of goods or approved by 101 Zydus Lifesciences Limited Zydus Pharmaceuticals UK Ltd. 84 Company services the Audit Committee Subsidiary 102 Zydus Lifesciences Limited Zydus Pharmaceuticals UK Ltd. Interest received N.A. Company German Remedies Pharma Subsidiary 103 39 Zvdus Lifesciences Limited nterest naid NΑ rivate Limited Company vdus Animal Health and ubsidiary 104 Zvdus Lifesciences Limited nterest paid N.A 421 vestments Limited ompany Subsidiary 105 Zydus Lifesciences Limited Zvdus Healthcare Limited nterest paid N.A. 1.399 ompany Any other ubsidiary 106 Zydus Lifesciences Limited ydus Foundation Advance for CSR N.A. 204 ompany Corporate Social Subsidiary Any other 107 Zvdus Lifesciences Limited Zvdus Foundation Responsibility NΑ 348 transaction Company (CSR) Expenses Subsidiary 1 Month SOFR + 180 108 Zvdus Lifesciences Limited entynl Therapeutics Inc. loan N.A. 4,661 Loans 5 Year Unsecured Business Purpose ompany LM Manufacturing India Subsidiary 109 Zvdus Lifesciences Limited N.A nterest received Private Limited Company Outstanding LM Manufacturing India Subsidiary Any other 110 Zydus Lifesciences Limited Receivables -N.A Private Limited transaction Company oans Subsidiary 111 7vdus Lifesciences Limited nvestment NΑ 550 7,050 7.600 NΑ N.A Rusiness Purnose Zvdus Pharmaceuticals Limited Investment Unsecured ompany Zydus Pharmaceuticals Canada Subsidiary 112 Zvdus Lifesciences Limited nvestment N.A 84 ompany Subsidiary 113 436 360 797 N.A N.A Zydus Lifesciences Limited Zynext Ventures Pte. Ltd. nvestment N.A Investment Unsecured **Business Purpose** ompany ydus Pharmaceuticals (USA) Subsidiary 114 Zydus Lifesciences Limited N.A. 4,623 ompany Subsidiary 115 Zydus Lifesciences Limited Zydus Healthcare Limited N.A. 1,272 Loan Company Subsidiary 116 Zydus Lifesciences Limited Zydus Worldwide DMCC N.A. 1,743 oan ompany Zydus Animal Health and Subsidiary Zydus Lifesciences Limited 192 Loan nvestments Limited Company Contributions during the year Post Any other Cadila Healthcare Ltd. 118 Zydus Lifesciences Limited 275 Employment fincludes NΑ Managerial Cadre EPF ransaction Benefit Plans Employee's share and contribution Contributions Cadila Healthcare Limited Post during the year Any other 119 Zydus Lifesciences Limited Employees Group Gratuity Employment [includes 480 ransaction Benefit Plans Employee's share and contribution

11,670

11,451

Zvdus Animal Health and

nvestments Limited

120 Zydus Lifesciences Limited

Subsidiary

Company

Anv other

ransaction

Outstanding

Payables - Loans

															once, dur	ing the repo	rting period w	hen such transaction	was underta	aken.	•
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related	Damada .	Value of the related	Date of Audit	Value of	In case monie either party a the trans	s a result of	m	y financials ind ake or give load				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
121	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.			-	36,638	42,347	-		-	-	-	-	-	-	-
122	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.			-	1,037	1,035	-		-	-	-	-	-	-	-
123	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	470	442	-		-	-	-	-	-	-	-
124	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	135	11	-		-	-	-	-	-	-	-
125	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	401	379	-		-	-	-	-	-	-	-
126	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	733	650	-		-	-	-	-	-	-	-
127	Zydus Lifesciences Limited	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	37	62	-		-	-	-	-	-	-	-
128	Zydus Lifesciences Limited	Nesher Pharmaceuticals (USA) LLC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1	-	-		-	-	-	-	-	-	-
129	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	75	75	-		-	-	-	-	-	-	-
130	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	302	291	-		-	-	-	-	-	-	-
131	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	48	60	-		-	-	-	-	-	-	-
132	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	60	79	-		-	-	-	-	-	-	-
133	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	273	249	-		-	-	-	-	-	-	-
134	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	2	2	-		-	-	-	-	-	-	-
135	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Sale of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-

															once, du	ring the repo	rting period v	vhen such transaction	was undert	aken.	
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of the related	Date of Audit	Value of	In case monie either party a the trans	s a result of	in case an	y financials ind nake or give loa				Details (of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/issuance of debt/any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
136	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1	0	-		-	-	-	-	-	-	_
137	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1	-	-		-	-	-	-	-	-	_
138	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	88	13	-		-	-	-	-	-	-	_
139	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	10	15	-		-	-	-	-	-	-	-
140	Zydus Lifesciences Limited	Sterling Biotech Limited	Joint Ventures	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	15	7	-		-	-	-	-	-	-	-
141	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	61	2	-		-	-	-	-	-	-	-
142	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1	0	-		-	-	-	-	-	-	-
143	Zydus Lifesciences Limited	Vitely Bio LLP	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1	0	-		-	-	-	-	-	-	-
144	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-
145	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Enterprises significantly	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	1	-		-	-	-	-	-	-	-
146	Zydus Lifesciences Limited	Oneiro Chemicals Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	141	113	-		-	-	-	-	-	-	-
147	Zydus Lifesciences Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	25	10	-		-	-	-	-	-	-	_

													, i	• •	once, dur	ing the repo	rting period w	when such transaction	was underta	aken.	1
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of the related	Date of Audit	Value of	In case monie either party a the trans	s a result of		y financials inde ake or give loar				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
148	Zydus Lifesciences Limited	Aleta Hospitals LLP [Formerly known as Zydus Hospitals (Vadodara) LLP]	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	0				-	-	-	-	-	-
149	Zydus Lifesciences Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	196	-		-	-	-	-	-	-	-
150	Zydus Lifesciences Limited	Mr. Ganesh N. Nayak	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	82	-		-	-	-	-	-	-	-
151	Zydus Lifesciences Limited	Mr. Nitin D. Parekh	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	3	-		-	-	-	-	-	-	-
152	Zydus Lifesciences Limited	Mr. Dhaval N. Soni	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	0	-		-	-	-	-	-	-	-
153	Zydus Lifesciences Limited	Dialforhealth Unity Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	2	3	-		-	-	-	-	-	-	-
154	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	230	228	-		-	-	-	-	-	-	-
155	Zydus Lifesciences Limited	Zydus International Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	13,405	12,582	-		-	-	-	-		-	-
156	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables -		N.A.	 		-	13,822	9,396	-		-	-	-	-	-	-	-
157	Zydus Lifesciences Limited	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Loans Outstanding Receivables -	-	N.A.			-	5,445	10,250	-		-	-	-	-	-	-	_
158	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Loans Outstanding Receivables -	-	N.A.			-	9,765	8,263	-		-	-	-	-	-	-	-
159	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Loans Outstanding Receivables - Other than loans		N.A.			-	204	242	-		-	-	-	-	-	-	-
160	Zydus Lifesciences Limited	Zydus Wellness Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	4	1	-		-	-	-	-	-	-	-
161	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	11	1	-		-	-	-	-	-	-	-
162	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	4	5	-		-	-	-	-	-	-	-
163	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	104	74	-		-	-	-	-	-	-	-

															once, dur	ing the repo	rting period w	hen such transaction	was underta	aken.	Í
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related	Dame 1	Value of the related	Date of Audit	Value of	In case monie either party a the trans	s a result of	m	y financials ind ake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
164	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	3	1	-		-	-	-	-	-	-	-
165	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	595	295	-		-	-	-	-	-	-	-
166	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	37,989	61,770	-		-	-	-	-	-	-	-
167	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1,344	1,797	-		-	-	-	-	-	-	-
168	Zydus Lifesciences Limited	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	47	17	-		-	-	-	-	-	-	-
169	Zydus Lifesciences Limited	Zydus Healthcare Philippines Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	291	210	-		-	-	-	-	-	-	-
170	Zydus Lifesciences Limited	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	841	702	-		-	-	-	-	-	-	-
171	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	908	1,012	-		-	-	-	-	-	-	-
172	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	877	1,371	-		-	-	-	-	-	-	-
173	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1,254	1,791	-		-	-	-	-	-	-	-
174	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	716	893	-		-	-	-	-	-	-	-
175	Zydus Lifesciences Limited	Etna Biotech S.R.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	76	76	-		-	-	-	-	-	-	-
176	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	131	96	-		-	-	-	-	-	-	-
177	Zydus Lifesciences Limited	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	236	248	-		-	-	-	-	-	-	-
178	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	227	409	-		-	-	-	-	-	-	-

Amount in INR Million except stated otherwise Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. Details of the party entering In case monies are due to In case any financials indebtedness is incurred to Details of the counterparty Value of the Date of either party as a result of Details of loans/ investments /alue of the make or give loans/ investments the transaction related Audit the transaction related Value of Committee party Details of other Nature of party transaction Relationship Type of Related ransaction approval by Meeting Nature indebtedr Purpose for which related party ransactio during the of the (loan/ No **Party Transaction** as audit where the transactions ratified by reporting ess (loan/ Details of the funds will be Secured/ counterparty approved by committee ratification Opening Closing advance/ other Interest Rate (%) utilised by the Name Name the audit issuance Cost Tenure Tenure period with the lister the audit was balance balance intercorpora Unsecured of debt/ ndebtedness ltimate recipient o committee entity or its te deposit/ committee approved any other funds (endusage) subsidiary investment etc.) Enterprises ignificantly Zydus Hospitals and Outstanding nfluenced by Any other 179 Zydus Lifesciences Limited Healthcare Research Private Receivables -10 N.A Directors and/ transaction Other than loans or their relatives Enterprises significantly Amount as Oneiro Chemicals Private influenced by Purchase of goods or approved by 180 Zydus Healthcare Limited Limited Directors and/ services the Audit or their Committee relatives Amount as 0 approved by Zydus Nikkho Farmaceutica Subsidiary Purchase of goods or 181 Zydus Healthcare Limited Ltda. services the Audit Company Committee Enterprises significantly Amount as Cadmach Machinery Company influenced by Purchase of goods or approved by 182 Zydus Healthcare Limited rivate Limited Directors and/ services the Audit or their Committee relatives Enterprises significantly Amount as Zydus Hospitals and nfluenced by Purchase of goods or approved by 183 Zydus Healthcare Limited Healthcare Research Private Directors and/ services the Audit Limited or their Committee. relatives Enterprises significantly Amount as Mukesh M. Patel & Co., Purchase of goods or influenced by approved by 184 Zydus Healthcare Limited roprietorship Firm Directors and/ services the Audit Committee. or their relatives Amount as German Remedies Pharma Subsidiary Sale of goods or approved by 62 62 185 Zydus Healthcare Limited rivate Limited the Audit Company services Committee. Enterprises significantly Amount as Zvdus Hospitals and nfluenced by Sale of goods or approved by 186 Zydus Healthcare Limited Healthcare Research Private 18 18 Directors and/ services the Audit imited or their Committee. relatives Enterprises significantly Amount as Sale of goods or influenced by approved by 187 Zydus Healthcare Limited Ramanbhai Foundation Directors and/ services the Audit or their Committee. relatives Amount as Zydus Wellness Products Subsidiary Sale of goods or approved by 188 Zydus Healthcare Limited imited Company services the Audit Committee Any other Director Sitting

189 Zydus Healthcare Limited

Dr. Sharvil P. Patel

Managerial

ransaction

															once, dur	ing the repo	orting period v	when such transaction	was undert	aken.	,
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of the	Date of Audit	V.1 .	In case monie either party a the trans	s a result of		y financials indo	ebtedness is i	ncurred to			of loans/ inv		
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	related party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/issuance of debt/any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
190	Zydus Healthcare Limited	Mr. Nitin D. Parekh	Key Managerial Personnel	Any other transaction	Director Sitting Fees	-	N.A.			0	-	-	-		-	-	-	-	-	-	-
191	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Interest received		-	N.A.			3	-	-	-		-	-	-	-	-	-	-
192	Zydus Healthcare Limited	Zydus Foundation	Subsidiary Company	Any other transaction	Corporate Social Responsibility (CSR) Expenses	-	N.A.			147	-	-	-		-	-	-	-	-	-	-
193	Zydus Healthcare Limited	Zydus Foundation	Subsidiary Company	Sale of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
194	Zydus Healthcare Limited	Zydus Foundation	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	0	-		-	-	-	-	-	-	-
195	Zydus Healthcare Limited	Zydus Foundation	Subsidiary Company	Any other transaction	Advance for CSR	-	N.A.			150	-	-	-		-	-	-	-	-	-	-
196	Zydus Healthcare Limited	Recon Pharmaceuticals and Investments	Subsidiary Company	Investment		-	N.A.			901	-	-	-		-	-	-	-	-	-	-
197	Zydus Healthcare Limited	Zydus Lifesciences Limited	Parent Company	Loan	<u></u>	-	N.A.			6,896	-	-	-		-	-	Loans	1 Month T Bill + 35 BPS	5 Year	Unsecured	Business Purpose
198	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Loan		-	N.A.			300	-	-	-		-	-	Loans	0	2 Month	Unsecured	Business Purpose
199	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Loan		-	N.A.			300	-	-	-		-	-	-	-	-	-	-
200	Zydus Healthcare Limited	Recon Pharmaceuticals and Investments	Subsidiary Company	Any other transaction	Share of profit Received	-	N.A.			0	-	-	-		-	-	-	-	-	-	-
201	Zydus Healthcare Limited	Zydus Healthcare Limited Employees Group Gratuity Scheme	Post Employment Benefit Plans	Any other transaction	Contributions during the year (includes Employee's share and contribution)	-	N.A.			52	-	-	-		-	-	-	-	-	-	-
202	Zydus Healthcare Limited	Zydus Wellness Limited	Subsidiary Company	Loan		-	N.A.			700	-	-	-		-	-	Loans	1 Year T bill + 90 bps	1 Year	Unsecured	Business Purpose
203	Zydus Healthcare Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-
204	Zydus Healthcare Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1	1	-		-	-	-	-	-	-	-
205	Zydus Healthcare Limited	Ramanbhai Foundation	Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	0	-		-	-	-	-	-	-	-
206	Zydus Healthcare Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	11	8	-		-	-	-	-	-	-	-

Amount in INR Million except stated otherwise Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. Details of the party entering In case monies are due to In case any financials indebtedness is incurred to Details of the counterparty Value of the Date of either party as a result of Details of loans/ investments /alue of the make or give loans/ investments the transaction related Audit the transaction related Value of Committee party Nature of Details of other party transaction Relationship Type of Related ransaction approval by Meeting Nature indebtedr Purpose for which related party ransactio during the of the (loan/ No **Party Transaction** as audit where the transactions ratified by reporting ess (loan/ Details of the funds will be Secured/ counterparty approved by committee ratification Opening Closing advance/ other Interest Rate (%) utilised by the Name Name the audit period issuance Cost Tenure Tenure with the lister balance the audit was balance intercorpora Unsecured of debt/ ndebtedness ltimate recipient o committee entity or its te deposit/ committee approved any other funds (endusage) subsidiary investment etc.) mount as Zydus Wellness Products Subsidiary Purchase of goods or approved by 207 Zydus Wellness Limited 82 the Audit imited Company services Committee. Enterprises significantly Amount as Mukesh M. Patel & Co., influenced by Purchase of goods or approved by 208 Zydus Wellness Limited Proprietorship Firm Directors and/ services the Audit or their Committee relatives Subsidiary 209 Zydus Wellness Limited 350 N.A Zydus Healthcare Limited loan Company Subsidiary 210 18 Zydus Wellness Limited Zydus Healthcare Limited nterest paid N.A Company ubsidiary Any other Outstanding 211 Zydus Wellness Limited Zvdus Healthcare Limited 358 NΑ Company transaction Pavables - Loans Corporate Social Any other Subsidiary 212 Zydus Wellness Limited Zydus Foundation Responsibility N.A. Company ransaction (CSR) Expenses Amount as Zydus Wellness Products Subsidiary Sale of goods or approved by 213 Zydus Wellness Limited 1,417 1,417 imited services the Audit Committee. mount as Zydus Wellness International Subsidiary Sale of goods or approved by 214 Zydus Wellness Limited 21 21 the Audit Company services Committee Amount as Zydus Wellness Products Subsidiary approved by 215 Zydus Wellness Limited Sale of fixed assets Limited Company the Audit Committee Amount as Zvdus Wellness Products Subsidiary Sale of goods or approved by 216 Zydus Wellness Limited 214 214 imited Company services the Audit Committee Zydus Wellness Products Subsidiary 217 Zydus Wellness Limited N.A. nterest paid Ω imited Company ydus Wellness Products Subsidiary 218 Zydus Wellness Limited N.A. 440 imited ompany Amount as Reimhursement Subsidiary Anv other approved by Zvdus Wellness International 219 Zydus Wellness Limited of Expenses DMCC Company transaction the Audit Recovered Committee Key Any other Director Sitting 220 Zydus Wellness Limited Dr. Sharvil P. Patel N.A Managerial ransaction Personnel Any other Director Sitting

221 Zydus Wellness Limited

Mr. Ganesh N. Nayak

Managerial

Personnel

ransaction

															once, dur	ing the repo	rting period v	when such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of the related	Date of Audit	Value of	In case monies either party a the trans	s a result of	in case an	y financials ind ake or give loa	ebtedness is i	ncurred to			of loans/ inv		
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
222	Zydus Wellness Limited	Mr. Tarun Arora	Key Managerial Personnel	Remuneration		-	N.A.			7	-	-	-		-	-	-	-	-	-	-
223	Zydus Wellness Limited	Mr. Umesh V. Parikh	Key Managerial Personnel	Remuneration		-	N.A.			10	-	-	-		-	-	-	-	-	-	-
224	Zydus Wellness Limited	Mr. Nandish P. Joshi	Key Managerial Personnel	Remuneration		-	N.A.			1	-	-	-		-	-	-	-	-	-	-
225	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Interest received		-	N.A.			20	-	-	-		-	-	-	-	-	-	-
226	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Interest received		-	N.A.			7	-	-	-		-	-	-	-	-	-	-
227	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Loan		-	N.A.			53	-	-	-		-	-	Loans	6 Month SOFR + 150 BPS	2 Year	Unsecured	Business Purpose
228	Zydus Pharmaceuticals Limited	Zydus Pharmaceuticals Limited Employees Group Gratuity Scheme	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.			7	-	-	-		-	-	-	-	-	-	-
229		Zydus Wellness Limited Employees Group Gratuity Scheme	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.			5	-	-	-		-	-	-	-	-	-	-
230	Zydus Wellness Limited	Mr. Tarun Arora	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	-	-		-	-	-	-	-	-	-
231	Zydus Wellness Limited	Mr. Umesh V. Parikh	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1	5	-		-	-	-	-	-	-	-
232	Zydus Wellness Limited	Mr. Nandish P. Joshi	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	-	-		-	-	-	-	-	-	-
233	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	2,058	-	-		-	-	-	-	-	-	-
234	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	196	243	-		-	-	-	-	-	-	-
235	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.		_	-	-	44	-		-	-	-	-	-	-	-
236	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.			-	-	440	-		-	-	-	-	-	-	-
237	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	124	-	-		-	-	-	-	-	-	-
238	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	20	35	-		-	-	-	-	-	-	-

Zydus Lifesciences Limited Disclosure of related party transactions for the half year/ six months ended March 31, 2025 Amount in INR Million except stated otherwise Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

	Details of the party entering into the transaction	Details of the counte	erparty			Value of the related		Value of the related	Date of Audit	Value of	In case monie either party a the trans	s a result of		y financials ind ake or give loa			Tring period w		of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/issuance of debt/any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
239	Zydus Wellness Products Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of fixed assets		-	N.A.			2	-	-	-		-	-	-	-	-	-	-
240	Zydus Wellness Products Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly	Purchase of goods or services		-	N.A.			1	-	-	-		-	-	-	-	-	-	-
241	Limited	Mr. Tarun Arora	Key Managerial Personnel	Remuneration		-	N.A.			52	-	-	-		-	-	-	-	-	-	-
242	Zudus Wallness Bradusts	Zydus Wellness International DMCC	Subsidiary Company Subsidiary	Sale of goods or services Sale of goods or		-	N.A.			96 45	-	-	-		-	-	-	-	-	-	
243	Limited Zydus Wellness Products Limited	Zydus Healthcare Limited Zydus Wellness International DMCC	Company	services Sale of goods or services		-	N.A.			2	-	-	-		-	-	-	- -	-	-	
245	Zydus Wellness Products Limited	Zydus Healthcare Limited	Company Subsidiary Company	Sale of goods or services		-	N.A.			5	-	-	-		-	-	-	-	-	-	-
246	Zydus Wellness Products Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			21	-	-	-		-	-	-	-	-	-	-
247	Zydus Wellness Products Limited	LM Manufacturing India Private Limited	Subsidiary Company	Sale of goods or services		-	N.A.			3	-	-	-		-	-	-	-	-	-	-
248	Zydus Wellness Products Limited	LM Manufacturing India Private Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-	-
249	Zydus Wellness Products Limited	LM Manufacturing India Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	0	-		-	-	-	-	-	-	-
250	Zydus Wellness Products Limited	Heinz India Private Limited Provident Fund	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.			2	-	-	-		-	-	-	-	-	-	-
251	Zydus Wellness Products Limited	Heinz India Private Limited Employee Provident Fund	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.			3	-	-	-		-	-	-	-	-	-	-
252	Zydus Wellness Products Limited	Heinz India Private Limited Pension Fund	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.			2	-	-	-		-	-	-	-	-	-	-
253	Zydus Wellness Products Limited	Zydus Wellness Sikkim Employees Group Gratuity Scheme	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]		N.A.			5	-	-	-		-	-	-	-	-	-	-

															once, dur	ing the repo	orting period v	when such transaction	was underta	ıken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of the related	Date of Audit	Value of	In case monie either party a the trans	s a result of		y financials indo	ebtedness is i	ncurred to			of loans/ inv		
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
254	Zydus Wellness Products Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	2	-	-		-	-	-	-	-	-	-
255	Zydus Wellness Products Limited	Mr. Tarun Arora	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	3	-	-		-	-	-	-	-	-	-
256	Zydus Wellness Products Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	187	214	-		-	-	-	-	-	-	-
257	Zydus Wellness Products Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	30	20	-		-	-	-	-	-	-	-
258	German Remedies Pharma Private Limited	German Remedies Pharmaceuticals Private Limited Emp Group Gratuity Scheme	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.			5	-	-	-		-	-	-	-	-	-	-
259	German Remedies Pharma Private Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services		-	N.A.	1	Ī	176	-	-	-		-	-	-	-	-	-	-
260	German Remedies Pharma	Zydus Foundation	Subsidiary Company	Any other transaction	Corporate Social Responsibility (CSR) Expenses	-	N.A.			12	-	-	-		-	-	-	-	-	-	-
261	German Remedies Pharma Private Limited	Recon Pharmaceuticals and Investments	Subsidiary Company	Any other transaction	Share of profit Received	-	N.A.			0	-	-	-		-	-	-	-	-	-	-
262	German Remedies Pharma	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	56	3	-		-	-	-	-	-	-	-
263	Zydus Pharmaceuticals Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			16	-	-	-		-	-	-	-	-	-	-
264	Zydus Pharmaceuticals Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			0	-	-	-		-	-	-	-	-	-	-
265	Zydus Pharmaceuticals Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Sale of goods or services		-	N.A.	1	1	15	-	-	-		-	-	-	-	-	-	-
266	Zydus Pharmaceuticals Limited	Zudus Infrastructure Private	Enterprises significantly influenced by Directors and/ or their relatives		Outstanding Payables - Other than loans	-	N.A.			-	10	5	-		-	-	-	-	-	-	-
267	Zydus Pharmaceuticals Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	49	15	-		-	-	-	-	-	-	-

No

Zydus Animal Health and

nvestments Limited

286

Zydus Medtech Private

imited

Subsidiary

Company

Any other

ransaction

Receivables

N.A.

Disclosure of related party transactions for the half year/ six months ended March 31, 2025 Amount in INR Million except stated otherwise Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. Details of the party entering In case monies are due to In case any financials indebtedness is incurred to Details of the counterparty Value of the Date of either narty as a result of Details of loans/ investments /alue of th make or give loans/ investments the transaction related Audit the transaction related Value of Committee party Details of other Nature of party transaction Relationship Type of Related ransaction approval by Meeting Nature indebtedr Purpose for which related party ransactio during the of the (loan/ **Party Transaction** as tibuc where the transactions ratified by reporting ess (loan/ Details of the funds will be counterparty approved by committee ratification Opening Closing advance/ Secured/ other Interest Rate (%) utilised by the Name Name the audit issuance Cost Tenure Tenure period with the lister the audit was balance balance intercorpora Unsecured of debt/ ndebtedness ltimate recipient o committee entity or its te deposit/ committee approved any othe funds (endusage) subsidiary investment etc.) Enterprises ignificantly Zydus Animal Health and Cadmach Machinery Company influenced by Purchase of goods or 268 N.A nvestments Limited Private Limited Directors and/ services or their relatives Zydus Animal Health and ubsidiary 269 Dialforhealth Unity Limited nterest received N.A. vestments Limited Outstanding Zydus Animal Health and ubsidiary Any other 270 Dialforhealth Unity Limited Receivables -N.A 0 nvestments Limited Company transaction Loans Zydus Animal Health and 271 Sterling Biotech Limited oint Venture Investment N.A. 208 6,500 6,708 Investment N.A N.A Insecured **Business Purpose** vestments Limited Zydus Animal Health and Subsidiary 272 iona Pharmaceuticals INC N.A. 419 nvestment vestments Limited ompany Zvdus Animal Health and Zvdus Medtech Private Subsidiary 273 nvestment N.A. 150 245 Investment N.A Insecured **Business Purpose** vestments Limited ompany Zydus Animal Health and Zvdus Medtech Private Subsidiary 395 nvestment N.A. Investments Limited imited Company Zvdus Medtech Private Zydus Animal Health and Subsidiary 275 29 N.A nterest received nvestments Limited Limited Company Zydus Animal Health and Zydus Medtech Private Subsidiary 1 Month T Bill + 120 276 371 5 Year loan Loans Unsecured **Business Purpose** nvestments Limited imited Company Outstanding Zydus Animal Health and Zvdus Medtech Private Subsidiary Any other 277 Receivables -N.A. nvestments Limited imited Company ransaction Other than loan Enterprises ignificantly Zydus Animal Health and Zvdus Infrastructure Private Purchase of goods or nfluenced by 278 vestments Limited imited Directors and/ services or their relatives Zydus Animal Health and Subsidiary Sale of goods or 279 7vVet Animal Health Inc 877 NΑ vestments Limited Company ervices ydus Animal Health and ubsidiary 280 Viona Pharmaceuticals INC nterest received N.A 11 nvestments Limited ompany Corporate Socia Zydus Animal Health and Subsidiary Any other 281 vdus Foundation Responsibility N.A 18 vestments Limited Company ransaction (CSR) Expenses Outstanding Zydus Animal Health and Subsidiary Any other 282 173 7vVet Animal Health Inc Pavables - Othe N.A. 51 Investments Limited transaction Company than loans Enterprises significantly Outstanding Zydus Animal Health and Cadmach Machinery Company influenced by Any other 283 Pavables - Othe 0 N.A nvestments Limited Private Limited Directors and/ transaction than loans r their elatives Enterprises ignificantly Outstanding Zydus Animal Health and Zydus Infrastructure Private nfluenced by Any other 284 Payables - Other N.A. 2 nvestments Limited imited Directors and/ transaction than loans or their elatives Outstanding Zydus Animal Health and Any other ubsidiary 285 Viona Pharmaceuticals INC Receivables 419 427 nvestments Limited transaction ompany Outstanding

647

1,033

	1			•	,	1	,								once, dur	ing the repo	rting period w	hen such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of the	Date of Audit		In case monies either party a the trans	s a result of	in case an	y financials ind ake or give loa				Details o	of loans/ inve	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	related party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/issuance of debt/any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
287	Zydus Animal Health and Investments Limited	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	932	860	-		-	-	-	-	-	-	-
288	Recon Pharmaceuticals and Investments	Zydus Foundation	Subsidiary Company	Interest received		-	N.A.			0	-	-	-		-	-	-	-	-	-	-
289	Recon Pharmaceuticals and Investments	Zydus Medtech Private Limited	Subsidiary Company	Sale of goods or services		-	N.A.			3	-		-		-	-	-	-	-	-	-
290	Recon Pharmaceuticals and	Zydus Foundation	Subsidiary	Investment		-	N.A.		l—	900	-		†		-		-	-	-	-	-
291	Investments Zydus Pharmaceuticals (USA) Inc.	NAI Laboratories Limited	Company Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			90	-	-	-		-	-	-	-	-	-	-
292	Zydus Pharmaceuticals (USA) Inc.	Navinta III, Inc	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			63	-	-	-		-	-	-	-	-	-	-
293	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			219	-	-	-		-	-	-	-	-	-	-
294	Zydus Pharmaceuticals (USA) Inc.	Navinta NV, Inc.	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			270	-	-	-		-	-	-	-	-	-	-
295	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Sale of goods or services		-	N.A.			3	-	-	-		-	-	-	-	-	-	-
296	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		-	N.A.			3	-	-	-		-	-	-		-	-	-
297	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Sale of goods or services		-	N.A.			3	-	-	-		-	-	-	-	-	-	-
298	Zydus Pharmaceuticals (USA)	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Purchase of goods or services		-	N.A.		 	4,694	-	-	-		-	-	-	-	-	-	-
299		Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			123	-	-	-		- -	-	-	-	-	-	-
300		Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	-	N.A.			686	-	-	-		-	-	-	-	-	-	-
301		Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	2,775	4,357	-		-	-	-	-	-	-	-
302	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	-	N.A.			0	-	-	-		-	-	-	-	-	-	-
303	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Reimbursement of Expenses paid	-	N.A.			8	-	-	-		-	-	-	-	-	-	-

															once, dur	ing the repo	rting period w	hen such transaction	was underta	ken.	
	Details of the party entering into the transaction	Details of the counter	party			Value of the related		Value of the	Date of Audit		In case monie either party a the trans	s a result of		y financials ind ake or give loa				Details o	of loans/ inve	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	related party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
304	Zydus Pharmaceuticals (USA) Inc.		Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-	-
305	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			2	-	-	-		-	-	-	-	-	-	-
306	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			4	-	-	-		-	-	-	-	-	-	-
307	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			2	-	-	-		-	-	-	-	-	-	-
308	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-	-
309	Zydus Pharmaceuticals (USA) Inc.	Mahadev Management Inc.	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			65	-	-	-		-	-	-	-	-	-	-
310	Zydus Pharmaceuticals (USA) Inc.	Zydus Healthcare (USA) LLC	Subsidiary Company	Interest received		-	N.A.			6	-	-	-		-	-	-	-	-	-	-
311	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Interest received		-	N.A.	ļ		96	-	-	-		-	-	-	-	-	-	-
312	Zydus Pharmaceuticals (USA) Inc. Zydus Pharmaceuticals (USA)	Viona Pharmaceuticals INC	Subsidiary Company Subsidiary	Interest received		-	N.A.	ļ 		20	-		-		-		-	-	-	-	-
313	Inc. Zydus Pharmaceuticals (USA)	Zyvet Animai Health Inc	Company Subsidiary	Interest received		-	N.A.			2	-		-		-	-	-	-	-	-	-
314	Inc.	Zydus Therapeutics INC	Company	Interest received	Reimbursement	-	N.A.			176	-				-		-	-	-	-	-
315	Zydus Pharmaceuticals (USA) Inc. Zydus Pharmaceuticals (USA)	Zydus Pharmaceuticals Canada Inc. Zydus Pharmaceuticals Canada	Company	Any other transaction	of Expenses Recovered	-	N.A.			0	-	-	-		-		-	-	-	-	-
316	Inc. Zydus Pharmaceuticals (USA)	Inc. Zydus Pharmaceuticals Canada Zydus Pharmaceuticals Canada	Company	Interest received		-	N.A.	1		1	-	-	-		-		-	3 Month SOFR + 50	-	-	-
317	Inc. Zydus Pharmaceuticals (USA)	Inc. Zydus Pharmaceuticals Canada	Company Subsidiary	Any other	Outstanding Receivables -	- - -	N.A.			42	- 8	51	-		-	- -	Loans -	BPS -	1 Year	Unsecured -	Business Purpose
319	Inc. Zydus Pharmaceuticals (USA) Inc.	Inc. Zydus Pharmaceuticals Canada Inc.	Company Subsidiary Company	Any other transaction	Loans Outstanding Receivables - Other than loans		N.A.			-	0	1	-		- -	-	-	-	-	-	-
320	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Loan		-	N.A.			187	-	-	-		-	-	Loans	6 Month SOFR + 50 BPS	1 Year	Unsecured	Business Purpose
321	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Loan		-	N.A.			364	-	-	-		-	-	Loans	6 Month SOFR + 50 BPS	1 Year	Unsecured	Business Purpose
322	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Loan		-	N.A.	ļ		1,589	-	-			-	-	Loans	6 Month SOFR + 50 BPS	1 Year	Unsecured	Business Purpose
323	Zydus Pharmaceuticals (USA) Inc. Zydus Pharmaceuticals (USA)	Sentynl Therapeutics Inc.	Subsidiary Company	Loan		-	N.A.	ļ 		729	-	-	-		-	-	Loans	6 Month SOFR + 50 BPS	1 Year	Unsecured	Business Purpose
324	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Loan	<u> </u>	-	N.A.	<u></u>		4,700	-	-	<u> </u>		-	-	-	-	-	-	-

Zydus Lifesciences Limited Disclosure of related party transactions for the half year/ six months ended March 31, 2025 Amount in INR Million except stated otherwise Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. In case monies are due to In case any financials indebtedness is incurred to Details of the party entering

	into the transaction	Details of the counter	rparty			Value of the related		Value of the related	Date of Audit	Value of	either party a the trans	s a result of		y financials ind ake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/issuance of debt/any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
325	Zydus Pharmaceuticals (USA) Inc.	NAI Laboratories Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	16	-		-	-	-	-	-	-	-
326	Zydus Pharmaceuticals (USA) Inc.	Navinta III, Inc	Enterprises significantly	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	0	-		-	-	-	-	-	-	-
327	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	Enterprises significantly	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	18	46	-		-	-	-	-	-	-	-
328	Zydus Pharmaceuticals (USA) Inc.		Enterprises significantly	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	89	-		-	-	-	-	-	-	-
329	Zydus Pharmaceuticals (USA) Inc.	Nesher Pharmaceuticals (USA) LLC	[Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	9,176	-	-		-	-	-	-	-	-	-
330	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	6,716	2,765	-		-	-	-	-	-	-	-
331	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	738	941	-		-	-	-	-	-	-	-
332	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	-	368	-		-	-	-	-	-	-	-
333	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	6,404	8,120	-		-	-	-	-	-	-	-
334	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	2	33	-		-	-	-	-	-	-	-
335	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	61	8	-		-	-	-	-	-	-	-
336	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1	4	-		-	-	-	-	-	-	-
337	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	_	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	30	33	-		-	-	-	-	-	-	-
338	Zydus Worldwide DMCC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	-	N.A.			522	-	-	-		-	-	-	-	-	-	-
339	Zydus Worldwide DMCC	Zydus Healthcare (USA) LLC	l	Any other transaction	Reimbursement of Expenses paid	-	N.A.			4	-	-	-		-	-	-	-	-	-	-
340	Zydus Worldwide DMCC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services	<u> </u>	-	N.A.			546	-	-	-		-	-	-	-	-	-	-

															once, du	ing the repo	rting period w	hen such transaction	was underta	aken.	
	Details of the party entering into	Details of the counter	rparty			Value of the related		Value of the	Date of Audit		In case monie	s a result of		y financials ind ake or give loa				Details o	of loans/ inv	estments	
S. No.	the transaction	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	related party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
341	Zydus Worldwide DMCC	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		-	N.A.			1	-	-	-		-	-	-	-	-	-	-
342	Zydus Worldwide DMCC	Zydus Netherlands B.V.	Subsidiary Company	Interest received		-	N.A.			25	-	-	-		-	-	-	-	-	-	-
343	Zydus Worldwide DMCC	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Interest received		-	N.A.			14	-	-	-		-	-	-	-	-	-	-
344	Zydus Worldwide DMCC	Etna Biotech S.R.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	70	-	-		-	-	-	-	-	-	-
345	Zydus Worldwide DMCC	Etna Biotech S.R.L.	Subsidiary Company	Interest received		-	N.A.			5	-	-	-		-	-	-	-	-	-	-
346	Zydus Worldwide DMCC	Zydus France, SAS	Subsidiary Company	Interest received		-	N.A.			2	-	-	-		-	-	-	-	-	-	-
347	Zydus Worldwide DMCC	Zydus France, SAS	Subsidiary Company	Loan		-	N.A.			211	-	-	-		-	-	Loans	6 Month EURIBOR + 125 BPS	5 Year	Unsecured	Business Purpose
348	Zydus Worldwide DMCC	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	-	216	-		-	-	-	-	-	-	-
349	Zydus Worldwide DMCC	Etna Biotech S.R.L.	Subsidiary Company	Loan		-	N.A.			22	-	-	-		-	-	Loans	6 Month SOFR + 125 BPS	5 Year	Unsecured	Business Purpose
350	Zydus Worldwide DMCC	Zydus International Private Limited	Subsidiary Company	Interest received		-	N.A.			229	-	-	-		-	-	-	-	-	-	-
351	Zydus Worldwide DMCC	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	528	553	-		-	-	-	-	-	-	-
352	Zydus Worldwide DMCC	Zydus Netherlands B.V.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	938	982	-		-	-	-	-	-	-	-
353	Zydus Worldwide DMCC	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	206	-	-		-	-	-	-	-	-	-
354	Zydus Worldwide DMCC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1,571	288	-		-	-	-	-	-	-	-
355	Viona Pharmaceuticals INC	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-	-
356	Viona Pharmaceuticals INC	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-
357	Viona Pharmaceuticals INC	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	0	-		-	-	-	-	-	-	-
358	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services		-	N.A.			19	-	-	-		-	-	-	-	-	-	-
359	Zydus Healthcare (USA) LLC	Zydus Therapeutics INC	Subsidiary Company	Sale of goods or services		-	N.A.			3	-	-	-		-	-	-	-	-	-	-
360	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-	-
361	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.			-	210	214	-		-	-	-	-	-	-	-
362	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	1	-		-	-	-	-	-	-	-

					,		,			•					once, dur	ing the repo	orting period v	vhen such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of the	Date of Audit		In case monies either party as the trans	s a result of	in case an	y financials ind ake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	related party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
363	Zydus Healthcare (USA) LLC	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	2	0	-		-	-	-	-	-	-	-
364	ZyVet Animal Health Inc	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			201	-	-	-		-	-	-	-	-	-	-
365	Zydus Wellness International DMCC	Zydus Worldwide DMCC	Subsidiary Company	Purchase of goods or services		-	N.A.			1	-	-	-		-	-	-	-	-	-	-
366	Zydus Wellness International DMCC	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	1	-		-	-	-	-	-	-	-
367	Zydus International Private Limited	RIC Chemicals LTD	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			2	-	-	-		-	-	-	-	-	-	-
368	Zydus International Private Limited	Zydus Netherlands B.V.	Subsidiary Company	Interest received			N.A.	·		5	-	-	-		-	-	-	-	-	-	-
369	Zydus International Private Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Interest received		-	N.A.			5	-	-	-		-	-	-	-	-	-	-
370	Zydus International Private Limited	Zydus France, SAS	Subsidiary Company	Interest received		-	N.A.			8	-	-	-		-	-	-	-	-	-	-
371	Zydus International Private Limited	Laboratorios Combix S.L.	Subsidiary Company	Interest received		-	N.A.			6	-	-	-		-	-	-	-	-	-	-
372	Zydus International Private Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Loan		-	N.A.			3,716	-	-	-		-	-	-	-	-	-	-
373	Zydus International Private Limited	Zydus Worldwide DMCC	Subsidiary Company	Loan		-	N.A.			3,716	-	-	-		-	-	-	-	-	-	-
374	Zydus International Private Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Interest received		-	N.A.			239	-	-	-		-	-	-	-	-	-	-
375	Zydus International Private Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	8,801	5,421	-		-	-	-	-	-	-	-
376	Zydus International Private Limited	[UAE]	Subsidiary Company	Loan		-	N.A.			684	-	-	-		-	-	-	-	-	-	-
377	Zydus International Private Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Interest received		-	N.A.			478	-	-	-		-	-	-	-	-	-	-
378	Zydus International Private Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	17,771	17,115	-		-	-	-	-	-	-	-
379	Zydus International Private Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.			-	8,947	5,417	-		-	-	-	-	-	-	-
380	Zydus International Private Limited	Zydus Netherlands B.V.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	252	256	-		-	-	-	-	-	-	-
381	Zydus International Private Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	365	368	-		-	-	-	-	-	-	-
382	Zydus International Private Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	450	455	-		-	-	-	-	-	-	-
383	Zydus International Private Limited	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	334	338	-		-	-	-	-	-	-	-
384	Zydus France, SAS	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-	-

Amount in INR Million except stated otherwise Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. Details of the party entering In case monies are due to In case any financials indebtedness is incurred to Details of the counterparty Value of the Date of either party as a result of Details of loans/ investments /alue of the make or give loans/ investments the transaction related Audit the transaction related Value of Committee party Details of other Nature of party transaction Relationship Type of Related ransaction approval by Meeting Nature indebted Purpose for which related party ransaction during the of the (loan/ No **Party Transaction** as audit where the transactions ratified by reporting ess (loan/ Details of the funds will be counterparty approved by committee ratification Opening Closing advance/ Secured/ other Interest Rate (%) utilised by the Name Name the audit issuance Cost Tenure Tenure period with the lister the audit was balance balance intercorpora Unsecured of debt/ ndebtedness ltimate recipient o committee entity or its te deposit/ committee approved any othe funds (endusage) subsidiary investment etc.) Reimhursement Any other Subsidiary 385 Zydus France, SAS Zydus Pharmaceuticals UK Ltd. of Expenses N.A transaction ompany Outstanding Subsidiary Any other 386 Zydus France, SAS Laboratorios Combix S.L. Receivables -N.A. 0 Company transaction Other than loan Outstanding Alidac Pharmaceuticals SA Subsidiary Anv other 387 Zydus Healthcare S.A. (Pty) Ltd Receivables -N.A 440 421 (Pty) Ltd Company ransaction Loans Outstanding Alidac Pharmaceuticals SA Subsidiary Any other 388 Zydus Healthcare S.A. (Pty) Ltd Receivables -N.A. 53 51 (Pty) Ltd Company transaction Other than loan Script Management Services Subsidiary Sale of goods or 389 Zydus Healthcare S.A. (Pty) Ltd 312 N.A (Pty) Ltd Company ervices Reimbursemen Script Management Services Any other 390 Zydus Healthcare S.A. (Pty) Ltd of Expenses (Pty) Ltd Company transaction Recovered Outstanding Any other Script Management Services Subsidiary 391 Zydus Healthcare S.A. (Pty) Ltd Receivables -N.A (Pty) Ltd ransaction Other than loan Zydus Pharmaceuticals Mexico Zydus Pharmaceuticals Mexico Subsidiary Purchase of goods or 392 N.A SA De CV Services Company SA De C.V. Company services nterprises significantly Zydus Healthcare Philippines nfluenced by Purchase of goods or 393 RJ Conception Law Office Directors and/ services or their relatives Enterprises significantly Alidac Healthcare (Myanmar) Cadmach Machinery Company influenced by Purchase of goods or 394 N.A Limited Private Limited Directors and/ services or their relatives Enterprises significantly Alidac Healthcare (Myanmar) Cadmach Machinery Company influenced by Purchase of goods or 395 N.A Limited Private Limited Directors and/ services or their relatives Enterprises ignificantly Outstanding Alidac Healthcare (Myanmar) Cadmach Machinery Company influenced by Any other 396 Receivables -N.A Private Limited Directors and/ transaction Other than loans or their relatives Subsidiary 397 427 N.A Zynext Ventures Pte. Ltd. 354 781 N.A Zynext Ventures USA LLC nvestment N.A Investment Unsecured **Business Purpose** ompany Reimbursement ubsidiary Any other Sentynl Therapeutics Inc. 398 Zynext Ventures USA LLC of Expenses N.A transaction Company Recovered Subsidiary 399 Zvdus Pharmaceuticals UK Ltd. LiaMeds Limited Interest received NΑ 26 Company Subsidiary 400 Zvdus Pharmaceuticals UK Ltd. Medsolutions (Europe) Limited Interest received NΑ Ω Company ubsidiary 401 57 Zydus Pharmaceuticals UK Ltd. LM Manufacturing Limited Interest received N.A. ompany

0

N.A.

Zydus Pharmaceuticals UK Ltd. Oncosol Limited

oint Ventures

															once, du	ring the repo	rting period w	hen such transaction	was undert	aken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of the	Date of Audit		In case monie either party a the trans	s a result of		y financials ind nake or give loa				Details o	of loans/ inv	estments	
S. No		Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	related party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
403	Zydus Pharmaceuticals UK Ltd.	LiqMeds Worldwide Limited	Subsidiary Company	Interest paid		-	N.A.			0	-	-	-		-	-	-	-	-	-	-
404	Zydus Pharmaceuticals UK Ltd.	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	1	-		-	-	-	-	-	-	-
405	Zydus Pharmaceuticals UK Ltd.	Oncosol Limited	Joint Ventures	Loan		-	N.A.			0	-	-	-		-	-	-	-	-	-	-
406	Zydus Pharmaceuticals UK Ltd.	Oncosol Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	0	-	-		-	-	-	-	-	-	-
407	Zydus Pharmaceuticals UK Ltd.	Medsolutions (Europe) Limited	Subsidiary Company	Loan		-	N.A.			0	-	-	-		-	-	-	-	-	-	-
408	Zydus Pharmaceuticals UK Ltd.	Medsolutions (Europe) Limited	Subsidiany	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	0	-	-		-	-	-	-	-	-	-
409	Zydus Pharmaceuticals UK Ltd.	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	9	-		-	-	-	-	-	-	-
410	Zydus Pharmaceuticals UK Ltd.	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	1,840	1,704	-		-	-	-	-	-	-	-
411	Zydus Pharmaceuticals UK Ltd.	LiqMeds Worldwide Limited	Subsidiary Company	Loan		-	N.A.			20	-	-	-		-	-	-	-	-	-	-
412	Zydus Pharmaceuticals UK Ltd.	LiqMeds Worldwide Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.			-	22	-	-		-	-	-	-	-	-	-
413	Zydus Pharmaceuticals UK Ltd.	LiqMeds Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	830	769	-		-	-	-	-	-	-	-
414	Zydus Lifesciences Global FZE [UAE]	Zydus Lifesciences Limited	Parent Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1,044	3,084	-		-	-	-	-	-	-	-
415	Zydus Lifesciences Global FZE [UAE]	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		-	N.A.			225	-	-	-		-	-	-	-	-	-	-
416	Zvdus Lifesciences Global FZF	Zydus Healthcare (USA) LLC	Subsidiary Company	Purchase of goods or services		-	N.A.			85	-		-		-		-	-	-	-	-
417	Zudus Lifessionses Clobal EZE	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	-	N.A.			15	-	-	-		-	-	-	-		-	-
418	Zydus Lifesciences Global FZE [UAE]	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	7	1	-		-	-	-	-	-	-	-
419	Zydus Lifesciences Global FZE [UAE]	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	128	166	-		-	-	-	-	-	-	-
420	LM Manufacturing Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			9	-	-	-		-	-	-	-	-	-	-
421	LM Manufacturing Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Sale of goods or services		-	N.A.			7	-	-	-		-	-	-	-	-	-	-
422	LiqMeds Worldwide Limited	LM Manufacturing Limited	Subsidiary Company	Sale of goods or services			N.A.			9	-	-	-		-	-	-	-	-	-	-
423	LiqMeds Worldwide Limited	LiqMeds Lifecare Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.		·—	-	-	0	-		-	-	-	-	-	-	-

	T	T		,											once, dur	ing the repo	rting period w	vhen such transaction	was underta	iken.	•
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of the related	Date of Audit	Value of	In case monie either party a the trans	s a result of	in case an	y financials ind ake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
424	LiqMeds Worldwide Limited	LiqMeds Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	18			-	-	-	-	-	-	-
425	LM Manufacturing Limited	Oncosol Limited	Joint Ventures	Sale of goods or services		-	N.A.			0	-	-	-		-	-	-	-	-	-	-
426	LM Manufacturing Limited	Oncosol Limited	Joint Ventures	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-	-
427	LiqMeds Lifecare Limited	Oncosol Limited	Joint Ventures	Sale of goods or services		-	N.A.			93	-	-	-		-	-	-	-	-	-	-
428	LM Manufacturing India Private Limited	LM Manufacturing Limited	Subsidiary Company	Sale of goods or services		-	N.A.			35	-	-	-		-	-	-	-	-	-	-
429	LiqMeds Worldwide Limited	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	437	937	-		-	-	-	-	-	-	-
430	LiqMeds Worldwide Limited	Oncosol Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-
431	LM Manufacturing Limited	Medsolutions (Europe) Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	2	-		-	-	-	-	-	-	-
432	LM Manufacturing Limited	Medsolutions (Europe) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	6	-	-		-	-	-	-	-	-	-
433	LM Manufacturing Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	9	-		-	-	-	-	-	-	-
434	LM Manufacturing Limited	Oncosol Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	8	8	-		-	-	-	-	-	-	-
435	LiqMeds Limited	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	230	340	-		-	-	-	-	-	-	-
436	LiqMeds Limited	LiqMeds Worldwide Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	57	-	-		-	-	-	-	-	-	-
437	LiqMeds Lifecare Limited	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	26	37	-		-	-	-	-	-	-	-
438	LM Manufacturing India Private Limited	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	13	-		-	-	-	-	-	-	-
439	LiqMeds Lifecare Limited	LiqMeds Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1	1	-		-	-	-	-	-	-	-
440	LiqMeds Lifecare Limited	Medsolutions (Europe) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	10	10	-		-	-	-	-	-	-	-

Amount in INR Million except stated otherwise Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only

													c.roi poi	are acposits, a				when such transaction			a to be alsolosed only
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related	Remarks on	Value of the related	Date of Audit Committee	Value of	In case monie either party a the trans	s a result of	m	y financials ind ake or give loa				Details (of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	approval by audit committee	party transaction ratified by the audit committee	Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
441	LiqMeds Lifecare Limited	Oncosol Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	4	117	-		-	-	-	-	-	-	-
442	Medsolutions (Europe) Limited	LiqMeds Worldwide Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	13	13	-		-	-	-	-	-	-	-
443	Medsolutions (Europe) Limited	Oncosol Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	0	-		-	-	-	-	-	-	-
444	Medsolutions (Europe) Limited	Oncosol Limited	Joint Ventures	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	-	-		-	-	-	-	-	-	-
445	Zydus Medtech Private Limited	Zydus Medtech France SAS	Subsidiary Company	Investment		-	N.A.			0	-	0	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose
446	Zydus Worldwide DMCC	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Interest received		-	N.A.	1		2	-	-	-		-	-	-	-	-	-	-
447	Zydus Worldwide DMCC		Subsidiary Company	Loan		-	N.A.			1,269	-	-	-		-	-	Loans	1 Month SOFR + 125 BPS	1 Month	Unsecured	Business Purpose
448	Zydus Worldwide DMCC		Subsidiary Company	Loan		-	N.A.	 		1,269	-	-	-		-	-	-	-	-	-	-
449	Zydus Worldwide DMCC	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	-	N.A.			37	-	-	-		-	-	-	-	-	-	-
450		Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	1,249	-		-	-	-	-	-	-	-
451	Zydus Worldwide DMCC	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Sale of fixed assets		-	N.A.	1		1,184	-	-	-		-	-	-	-	-	-	-
452	Zydus Healthcare S.A. (Pty) Ltd		Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			8	-	-	-		-	-	-	-	-	-	-
453	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Loan		-	N.A.			1,970	-	-	-		-	-	-	-	-	-	-
454	Zydus Foundation	AIA Engineering Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Contributions received	-	N.A.			5	-	-	-		-	-	-	-	-	-	-
455	Zydus Foundation	Cadmach Machinery Company Private Limited	Enterprises significantly	Any other transaction	Contributions received	-	N.A.			2	-	- -	-		-	-	-	-	-	-	-
456		Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Contributions received	-	N.A.			10	-	-	-		-	-	-	-	-	-	-

Zvdus	Lifesciences	Limite
-------	--------------	--------

Disclosure of related party transactions for the half year/ six months ended March 31, 2025

Amount in INR Million except stated otherwise

											Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans,										
ir de la companya de												intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.									
S. No.	Details of the party entering into the transaction	Details of the counte	erparty			transaction	Remarks on approval by audit committee	related party transaction ratified by the audit committee	Date of Audit	Audit mmittee leeting leere the lification was	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to				Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary		Details of other related party transactions				Meeting where the ratification was approved		Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
457	Zydus Foundation	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives		Contributions received	-	N.A.			4	-	-	-		-	-	-	-	-	-	-
458	Zydus Foundation	Zydus Takeda Healthcare Private Limited	Joint Ventures	Any other transaction	Contributions received	-	N.A.			25	-	-	-		-	-	-	-	-	-	-

Notes:

- 1 Amount mentioned as 0 denotes value less than INR 1 Million.
- 2 Opening and closing balance are not given where there was no transaction of Investment during the half year ended March 31, 2025.
- 3 Receivables / Payables other than loans represents combined balance against sales / purchase pertaining to goods/ propoerty, plant and equipment / various services / reimbursement of expenses. Hence shown separately.